argenx SE (ARGX) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Argenx Se.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.736 to prevent any background noise. After the speaker's remarks, there will be a question. 00:00:10.886 -- 00:00:16.393 Issued earlier today with our half-year 2025 financial results and second quarter business 00:00:16.393 -- 00:00:21.935 update. This can be found on our website along with the presentation for today's webcast. 00:00:21.935 -- 00:00:26.479 Before we begin on slide 2, I'd like to remind you that forward-looking statements may 00:00:26.479 -- 00:00:31.244 be presented during this call. These may include statements about our future expectations, 00:00:31.244 -- 00:00:36.289 clinical developments, regulatory timelines, the potential success of our product candidates, 00:00:36.289 -- 00:00:39.191 financial projections, and upcoming milestones. 00:00:39.191 -- 00:00:43.455 Actual results may differ materially from those indicated by these statements. 00:00:43.455 -- 00:00:47.439 Our GenX is not under any obligation to update statements regarding the future or to 00:00:47.439 -- 00:00:52.141 conform those statements in relation to actual results unless required by law. 00:00:52.141 -- 00:00:56.967 I'm joined on the call today by Tim Van Harmeren, Chief Executive Officer, Karl Gubitz, 00:00:56.967 -- 00:01:01.072 Chief Financial Officer, and Karen Massey, Chief Operating Officer. 00:01:01.072 -- 00:01:04.996 Luke Trojan, Chief Medical Officer, will be available during the Q&A. 00:01:04.996 -- 00:01:08.160 I'll now turn the call over to Tim. 00:01:08.160 -- 00:01:10.783 Thank you, Beth, and welcome, everyone. 00:01:10.783 -- 00:01:13.406 I'll begin on slide number three. 00:01:13.406 -- 00:01:18.513 Vision 2030 is our roadmap for long-term value creation, 00:01:18.513 -- 00:01:22.634 and I'm proud to say that we are exactly wh...